Clinical Trial

A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of HJB647 at two different doses in participants with chronic stable heart failure with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF).
Protocol Amendment History 2 changes
critical Recruitment opened 2026-04-16
notable Trial sites expanded: 0 -> 3 locations 2026-04-16
Trial Details
NCT Number NCT07465653
Lead Sponsor Novartis Pharmaceuticals
Conditions Heart Failure With Reduced Ejection Fraction
Enrollment 12 participants
Start Date 2026-03-18
Primary Completion 2026-09-24 (estimated)
Study Completion 2026-09-24 (estimated)
Updated on ClinicalTrials.gov 2026-07-08